survaxm
Vaccineexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2019 (NCT04013672)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04978727 | Phase 1 | Jan 1, 2022 | Pediatric Brain Tumor Consortium, State University of New York, Buffalo |
| NCT05163080 | Phase 2 | Nov 18, 2021 | Imaging Endpoints, MimiVax, LLC, Translational Drug Development, University of California, San Francisco |
| NCT04013672 | Phase 2 | Sep 29, 2019 | Case Western Reserve University, The Cleveland Clinic |
| NCT04802447 | N/A | — | State University of New York, Buffalo |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| State University of New York, Buffalo | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Imaging Endpoints | For profit | 1 | 0 | 1 | 2021 |
| MimiVax, LLC | For profit | 1 | 1 | 1 | 2021 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2022 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1